CHA₂DS₂-VASc Score Predicts In-Hospital and Long-Term Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Who Were Undergoing Primary Percutaneous Coronary Intervention

Abstract

CHADS-VASc score includes similar risk factors for coronary artery disease. We hypothesized that admission CHADS-VASc score might be predictive of adverse clinical outcomes for patients with ST-segment elevation myocardial infarction (STEMI) who were undergoing primary percutaneous coronary intervention. A total of 647 patients with STEMI enrolled in this study. The study population was divided into 2 groups according to their admission CHADS-VASc score. The low group (n = 521) was defined as CHADS-VASc score ≤2, and the high group (n = 126) was defined as CHADS-VASc score >2. Patients in the high group had significantly higher incidence of in-hospital cardiovascular mortality (8.7% vs 1.9%; P < .001). Long-term mortality was significantly frequent in the high group (13.4% vs 3.6%, P < .001). Hypertension, admission CHADS-VASc score, and Killip class >1 were independent predictors of long-term mortality. Admission CHA2DS2-VASc score >2 was identified as an effective cutoff point for long-term mortality (area under curve = 0.821; 95% confidence interval: 0.76-0.89; P < .001). CHADS-VASc score is a simple, very useful, easily remembered bedside score for predicting in-hospital and long-term adverse clinical outcomes in STEMI.

CHA2DS2-VASc score predicts contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction, who have undergone primary percutaneous coronary intervention

“…The proportion of patients with post-procedural TIMI grade < 3 was higher in the high-risk group compared to the other groups. The CHA 2 DS 2 -VASc score was shown to indicate the severity of coronary artery disease in previous studies [3]. Our results support these previous studies.…”

“…However, it was recognised to also be usefulin the prediction of the severity of coronary artery disease [2] and coronary artery disease-related mortality due to the presence of some common risk factors [3]. It may also be used for prediction of mortality and morbidity in congestive heart failure patients who are candidates for cardiac re-synchronisation treatment [4] and thrombotic events developing after percutaneous coronary intervention (PCI) [5].…”

Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention

“…This study revealed a dual prognostic utility of CHA2DS2-VASc for both suboptimal reperfusion and short-term mortality. This coincides with many studies who found a useful surrogate measure of in-hospital mortality independent of nore low [5,12,[14][15][16][17][18].…”

The Association Between Health Related Quality of Life and Five Year Mortality in Patients with ST-Elevated Myocardial Infarction

“…Bununla birlikte HT'nin, yine Mİ sonrası hastaların mortalitesini gösterdiği iyi bilinmektedir (39,40) . Yaş, DM, HT ve cinsiyet gibi STYMİ hastalarında mortaliteyi arttırdığı gösterilmiş faktörlerle birlikte EQ5D skorlarının çoklu Cox regresyon analizi ile değerlendi-rildiğinde indeks skorun mortalite artışını 5.5 kat daha fazla ön gördürdüğü çalışmamızda tespit edilmiştir (41) . EQ5D indeks skoru STYMİ hastalarında uzun dönemli mortalitenin bağım-sız bir ön gördürücüsü olarak değerlendirilmiştir.…”